GlobalData expects the global uveitis therapeutics market to grow at 26.4% annually for the next seven years, from $317m in 2010 to reach $1.6 billion by 2017. This significant growth is primarily attributed to increasing therapeutic options for the treatment of uveitis. In addition, the successful launch of some targeted therapies such as Luveniq (voclosporin), AIN457 and the approval of Humira may significantly stimulate market growth in the near future. However, the complex etiology of the condition will continue to be a barrier for market growth.
GlobalDatas analysis reveals the current competition in the uveitis therapeutics market is weak and the available treatment options have only been moderately successful in meeting market demand. The products currently available in the market are associated with low safety and as the products currently available do not serve the markets unmet need the market continues to present opportunities for stronger pipeline candidates. The extent of unmet need in the uveitis therapeutics market is considered to be at a high level and can be filled by technologically advanced products possessing improved safety and efficacy profiles which are disease targeting.
For Sample Pages, please click or add the below link to your browser:
GlobalDatas research found that there are currently 20 products in different stages of development. Luveniq, currently in NDA Filing and AIN457 and Humira in Phase III are the most promising products in the pipeline.
Luveniq, AIN457 and Humira have shown encouraging response rates in pretreated patients and have great potential in the uveitis therapeutics market. If approved, other pipeline candidates (currently in several other phases of development) will provide alternative treatment options to the current therapies. These products are expected to meet some of the unmet need and will provide physicians with a better choice in treating uveitis but may also lead to an intensely competitive market.
The current uveitis market is weak and the corticosteroids and immunosuppressant treatment options leave moderate levels of unmet need. The currently marketed treatment options have low safety profiles. Although uveitis is one of the leading causes of blindness, the medications available to reduce the inflammation have a low safety profile.
GlobalData, the industry analysis specialist, has released its new report, Uveitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Uveitis Therapeutics market. The report identifies the key trends shaping and driving the global Uveitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Uveitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782